Related Experiment Video
Updated: Jun 12, 2026
07:02
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Dimebolin in dementia.
Deepak Sachdeva1, Alistair Burns
1Moor Side Unit, Trafford General Hospital, Urmston, Manchester, UK.
CNS Neuroscience & Therapeutics
|June 18, 2010
Summary
Dimebolin, an antihistamine, shows promise for Alzheimer's disease treatment, offering a potential new option beyond current dementia therapies. Further research is ongoing to confirm its efficacy and safety for neurodegenerative disorders.
Area of Science:
- Neuroscience
- Pharmacology
- Gerontology
Background:
- Current Alzheimer's disease (AD) treatments, including acetylcholinesterase inhibitors and memantine, offer limited efficacy.
- AD affects millions globally, necessitating novel therapeutic strategies.
- Dimebolin, a Russian antihistamine, has emerged as a potential AD treatment.
Purpose of the Study:
- To review dimebolin's potential as a treatment for Alzheimer's type dementia.
- To explore proposed mechanisms of action for dimebolin in dementia treatment.
- To discuss the current status and future prospects of dimebolin for neurodegenerative disorders.
Main Methods:
- Literature review of existing studies on dimebolin and dementia.
- Examination of theoretical frameworks explaining dimebolin's therapeutic effects.
- Analysis of preliminary trial results and ongoing evaluations.
Main Results:
- Dimebolin has demonstrated potential in initial trials for Alzheimer's type dementia.
- The drug's nonselective antihistamine properties are being investigated for neuroprotective effects.
- Further clinical trials are underway to validate its efficacy.
Conclusions:
- Dimebolin represents a novel therapeutic candidate for Alzheimer's disease.
- Understanding its mechanisms may offer new insights into dementia treatment.
- Results from ongoing trials will determine dimebolin's future role in managing dementia.
Related Concept Videos
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...